Atrial fibrillation: Yesterday, today, and tomorrow

Background. Advances in electrophysiological research have led to a modern understanding of the mechanisms of atrial fibrillation — the most common sustained cardiac arrhythmia, which poses a risk of severe, often disabling, and fatal complications. Although there have also been advances in pharmacology and rapid progress in interventional treatment methods, atrial fibrillation still cannot be completely eliminated in patients. Objectives. To examine the key stages in the development and improvement of medical care for patients with atrial fibrillation from a historical perspective, taking into account the widely accepted rate and rhythm control strategies and using data from both international and Russian scientific literature. Methods. An analysis of literature sources by international and Russian authors dedicated to the issues of diagnosis, pharmacological, and non-pharmacological treatment of atrial fibrillation was carried out. In order to search for the sources, the Russian scientific electronic library eLibrary.ru and the biomedical research search engine PubMed were used. Results. Throughout the 20th and 21st centuries, antiarrhythmic drugs capable of successfully restoring sinus rhythm were developed; however, the challenge of its long-term maintenance with such medications has remained unresolved. The development and increasingly widespread use of surgical, and especially catheter ablation in the left atrium, have the potential to improve the effectiveness of atrial fibrillation treatment. Recently, the importance of individualizing the management strategy for patients with atrial fibrillation has been growing, with mandatory consideration of their clinical characteristics. The main direction for future research could be the development of more effective and safer antiarrhythmic drugs for their rational use in combination with innovative non-pharmacological treatment technologies for atrial fibrillation. Conclusion. This paper presents the most important advances in medical care for patients with atrial fibrillation. It outlines potential approaches to minimizing its negative impact on patients’ quality of life and prognosis

1. Lip GYH. Atrial Fibrillation in Clinical Practice. London: Martin Dunilz Ltd.; 2001. 234 p.

2. McMichael J. History of atrial fibrillation 1628–1819 Harvey — de Senac — Laënnec. Br Heart J. 1982;48(3):193–197. https://doi.org/10.1136/hrt.48.3.193

3. Garrey WE. Auricular fibrillation. Physiol. Rev. 1924;4:215–250. https://doi.org/10.1152/physrev.1924.4.2.215

4. Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model Of Atrial Fibrillation. Am Heart J. 1964;67:200–220. https://doi.org/10.1016/0002-8703(64)90371-0

5. Coumel P, Attuel P, Lavallée J, Flammang D, Leclercq JF, Slama R. Syndrome d’arythmie auriculaire d’origine vagale [The atrial arrhythmia syndrome of vagal origin]. Arch Mal Coeur Vaiss. 1978;71(6):645–656. French.

6. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res. 1988;62(2):395–410. https://doi.org/10.1152/10.1161/01.res.62.2.395

7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–1968. https://doi.org/10.1152/10.1161/01.cir.92.7.1954

8. Nishida K, Nattel S. Atrial fibrillation compendium: historical context and detailed translational perspective on an important clinical problem. Circ Res. 2014;114(9):1447–1452. https://doi.org/10.1152/10.1161/CIRCRESAHA.114.303466

9. Fazekas T. A pitvarremegés attekinto története [The concise history of atrial fibrillation]. Orvostort Kozl. 2007;53(3–4):37–68. Hungarian

10. Oral H, Morady F. Ablation of Cardiac Arrhythmias: Past, Present, and Future. Circulation. 2024;150(1):4–6. https://doi.org/10.1152/10.1161/CIRCULATIONAHA.124.068298

11. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD, Ko D, Weng LC, Lunetta KL, Frost L, Benjamin EJ, Trinquart L. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018;361:k1453. https://doi.org/10.1152/10.1136/bmj.k1453

12. Noubiap JJ, Tang JJ, Teraoka JT, Dewland TA, Marcus GM. Minimum National Prevalence of Diagnosed Atrial Fibrillation Inferred From California Acute Care Facilities. J Am Coll Cardiol. 2024;84(16):1501– 1508. https://doi.org/10.1152/10.1016/j.jacc.2024.07.014

13. Dai H, Zhang Q, Much AA, Maor E, Segev A, Beinart R, Adawi S, Lu Y, Bragazzi NL, Wu J. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574–582. https://doi.org/10.1152/10.1093/ehjqcco/qcaa061

14. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1– e156. https://doi.org/10.1152/10.1161/CIR.0000000000001193

15. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983– 988. https://doi.org/10.1152/10.1161/01.str.22.8.983. PMID: 1866765

16. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314– 3414. https://doi.org/10.1152/10.1093/eurheartj/ehae176

17. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373– 498. https://doi.org/10.1093/eurheartj/ehaa612

18. Zeitler EP, Chew DS, Mark DB. Opportunistic Screening for Subclinical Atrial Fibrillation: It Is Cost-Effective, but Is It Effective? Circ Cardiovasc Qual Outcomes. 2023;16(11):e010485. https://doi.org/10.1152/10.1161/CIRCOUTCOMES.123.010485

19. Kato Y, Tsutsui K, Nakano S, Hayashi T, Suda S. Cardioembolic Stroke: Past Advancements, Current Challenges, and Future Directions. Int J Mol Sci. 2024;25(11):5777. https://doi.org/10.1152/10.3390/ijms25115777

20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. https://doi.org/10.1152/10.7326/0003-4819-146-12-200706190-00007

21. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. https://doi.org/10.1152/10.1016/S0140-6736(13)62343-0

22. Lip GYH, Teppo K, Nielsen PB. CHA2DS2-VASc or a non-sex score (CHA2DS2-VA) for stroke risk prediction in atrial fibrillation: contemporary insights and clinical implications. Eur Heart J. 2024;45(36):3718–3720. https://doi.org/10.1152/10.1093/eurheartj/ehae540

23. Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma CS, Goodman SG, Oldgren J, Hammett C, Lopes RD, Akao M, De Caterina R, Kirchhof P, Gorog DA, Hemels M, Rienstra M, Jones WS, Harrington J, Lip GYH, Ellis SJ, Rockhold FW, Neumann C, Alexander JH, Viethen T, Hung J, Coppolecchia R, Mundl H, Caso V; OCEANIC-AF Steering Committee and Investigators. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2025;392(1):23–32. https://doi.org/10.1152/10.1056/NEJMoa2407105

24. Landmesser U, Skurk C, Tzikas A, Falk V, Reddy VY, Windecker S. Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives. Eur Heart J. 2024;45(32):2914–2932. https://doi.org/10.1152/10.1093/eurheartj/ehae398

25. Reynolds MR, Stein AB, Sun X, Hytopoulos E, Steinhubl SR, Cohen DJ. Cost-Effectiveness of AF Screening With 2-Week Patch Monitors: The mSToPS Study. Circ Cardiovasc Qual Outcomes. 2023;16(11):e009751. https://doi.org/10.1152/10.1161/CIRCOUTCOMES.122.009751

26. McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, Camm AJ, Goette A, Zapf A, Alings M, Connolly SJ, Kirchhof P, Lopes RD. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation. 2024;149(13):981– 988. https://doi.org/10.1152/10.1161/CIRCULATIONAHA.123.067512

27. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ; RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006 Nov;8(11):935–942. https://doi.org/10.1152/10.1093/europace/eul106

28. Lown B, Perlroth MG, Kaidbey S, ABE T, Harken DE. “Cardioversion” of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963;269:325–331. https://doi.org/10.1152/10.1056/NEJM196308152690701

29. Kraft M, Büscher A, Wiedmann F, L’hoste Y, Haefeli WE, Frey N, Katus HA, Schmidt C. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. Front Pharmacol. 2021 Mar 4;12:638445. https://doi.org/10.1152/10.3389/fphar.2021.638445. PMID: 33897427; PMCID: PMC8058608.

30. Lévy S. Cardioversion of recent-onset atrial fibrillation using intravenous antiarrhythmics: A European perspective. J Cardiovasc Electrophysiol. 2021;32(12):3259–3269. https://doi.org/10.1152/10.1111/jce.15264

31. Frey W. Ueber vorhofflimern beim menschen und seine beseitigung durch chiniden. Berl. Klin. Wschr. 1918;55:417–419.

32. Stiell IG, Sivilotti MLA, Taljaard M, Birnie D, Vadeboncoeur A, Hohl CM, McRae AD, Rowe BH, Brison RJ, Thiruganasambandamoorthy V, Macle L, Borgundvaag B, Morris J, Mercier E, Clement CM, Brinkhurst J, Sheehan C, Brown E, Nemnom MJ, Wells GA, Perry JJ. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet. 2020;395(10221):339–349. https://doi.org/10.1152/10.1016/S0140-6736(19)32994-0

33. Bellandi F, Dabizzi RP, Cantini F, Natale MD, Niccoli L. Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study. Cardiovasc Drugs Ther. 1996;10(2):153–157. https://doi.org/10.1152/10.1007/BF00823593

34. Reiffel JA, Capucci A. “Pill in the Pocket” Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation. Am J Cardiol. 2021;140:55–61. https://doi.org/10.1152/10.1016/j. amjcard.2020.10.063

35. Ruskin JN, Camm AJ, Dufton C, Woite-Silva AC, Tuininga Y, Badings E, De Jong JSSG, Oosterhof T, Aksoy I, Kuijper AFM, Van Gelder IC, van Dijk V, Nuyens D, Schellings D, Lee MY, Kowey PR, Crijns HJGM, Maupas J, Belardinelli L; INSTANT Investigators. Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial. JACC Clin Electrophysiol. 2024;10(6):1021– 1033. https://doi.org/10.1152/10.1016/j.jacep.2024.02.021

36. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003;89(2– 3):239–248. https://doi.org/10.1152/10.1016/s0167-5273(02)00477-1

37. Rozenshtraukh LV, Golitsyn SP. Antiarrhythmic medications nibentan and RG-2. Priroda. 2005;10(1082):51–52 (In Russ.).

38. Shubik IuV, Medvedev MM, Rivin AE. Nibentan — a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19–23 (In Russ.).

39. Mironov NYu, Vlodzyanovskiy VV, Yuricheva YuA, Sokolov SF, Golitsyn SP, Rosenstraukh LV, Chazov EI. Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology. 2018;14(5):664– 669 (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-5-664-669

40. Mironov NYu, Yuricheva YuA, Vlodzyanovskiy VV, Sokolov SF, Dzaurova KhM, Golitsyn SP, Shubik YuV, Berman MV, Medvedev MM, Rivin AE, Parkhomchuk DS, Barybin AE., Balandin DА, Batalov RE, Terekhov DS, Evstifeev IV, Kildeev IR, Pyataeva OV, Zenin SA. Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Car diology. 2021;17(2):193–199 (In Russ.). https://doi.org/10.20996/1819-6446-2021-03-05

41. Mironov NYu, Vlodzyanovskiy VV, Yuricheva YuA, Sokolov SF, Golitsyn SP, Rosenstraukh LV, Chazov EI. Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety. Rational Pharmacotherapy in Cardiology. 2018;14(6):826–830 (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-6-826-830

42. Mironov NYu, Yuricheva YuA, Vlodzyanovskiy VV, Sokolov SF, Dzaurova KhM, Golitsyn SP, Shubik YuV, Berman MV, Medvedev MM, Rivin AE, Parkhomchuk DS, Barybin AE, Balandin DА, Batalov RE, Terekhov DS, Evstifeev IV, Kildeev IR, Pyataeva OV, Zenin SA. Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology. 2021;17(2):193–199 (In Russ.). https://doi.org/10.20996/1819-6446-2021-03-05

43. Gagloeva DA, Mironov NYu, Dzaurova KhM, Zelberg MA, Yuricheva YuA, Sokolov SF, Golitsyn SP. Results of a prospective randomized study comparing efficacy and safety of refralon and amiodarone for cardioversion in patients with paroxysmal atrial fibrillation and flutter. Journal of Arrhythmology. 2024;31(1):63–70 (In Russ.). https://doi.org/10.35336/VA-1289

44. Arakelyan MG, Bockeria LA, Vasilieva EYu, Golitsyn SP, Golukhova EZ, Gorev MV, Davtyan KV, Drapkina OM, Kropacheva ES, Kuchinskaya EA, Lajovich LYu, Mironov NYu, Mishina IE, Panchenko EP, Revishvili ASh, Rzayev FG, Tatarsky BA, Utsumueva MD, Shakhmatova OO, Shlevkov NB, Shpektor AV, Andreev DA, Artyukhina EA, Barbarash OL, Galyavich AS, Duplyakov DV, Zenin SA, Lebedev DS, Mikhailov EN, Novikova NA, Popov SV, Filatov AG, Shlyakhto EV, Shubik YuV. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594 (In Russ). https://doi.org/1015829/1560-4071-2021-4594

45. Camm AJ, Naccarelli GV, Mittal S, Crijns HJGM, Hohnloser SH, Ma CS, Natale A, Turakhia MP, Kirchhof P. The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-ofthe-Art Review. J Am Coll Cardiol. 2022;79(19):1932–1948. https://doi.org/10.1016/j.jacc.2022.03.337

46. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825– 1833. https://doi.org/10.1056/NEJMoa021328

47. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbüchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305– 1316. https://doi.org/10.1056/NEJMoa2019422

48. Becher N, Metzner A, Toennis T, Kirchhof P, Schnabel RB. Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur Heart J. 2024;45(31):2824–2838. https://doi.org/10.1093/eurheartj/ehae373

49. Zafeiropoulos S, Doundoulakis I, Bekiaridou A, Farmakis IT, Papadopoulos GE, Coleman KM, Giannakoulas G, Zanos S, Tsiachris D, Duru F, Saguner AM, Mountantonakis SE, Stavrakis S. Rhythm vs Rate Control Strategy for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol. 2024;10(7 Pt 1):1395– 1405. https://doi.org/10.1016/j.jacep.2024.03.006

50. Rillig A, Eckardt L, Borof K, Camm AJ, Crijns HJGM, Goette A, Breithardt G, Lemoine MD, Metzner A, Rottner L, Schotten U, Vettorazzi E, Wegscheider K, Zapf A, Heidbuchel H, Willems S, Fabritz L, Schnabel RB, Magnussen C, Kirchhof P. Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial. Europace. 2024;26(6):euae121. https://doi.org/10.1093/europace/euae121

51. Shuvaev AN, Salmin VV, Kuvacheva NV, Pozhilenkova EA, Salmina AB. Modern tendencies in the development of the patch-clamp technique: new opportunities for neuropharmacology and neurobiology. Annals of Clinical and Experimental Neurology. 2015;9(4):54–57 (In Russ.).

52. Single-Channel Recording. Sakmann B, Neher E, editors. Springer US; 1995. 700 р. http://dx.doi.org/10.1007/978-1-4419-1229-9

53. Doshchitsin V.L., Tarzimanova A.I. Historical Aspects of the Use of Antiarrhythmic Drugs in Clinical Practice. Rational Pharmacotherapy in Cardiology. 2022;18(3):350–358 (In Russ.). https://doi.org/10.20996/1819-6446-2022-06-07

54. Kaverina NV, Berdyaev SYu, Kishchuk EP, Paskhina OE. Guidelines for the Study of Antiarrhythmic Activity of Pharmacological Substances Guide to Experimental (Preclinical) Study of New Pharmacological Substances. Ed. R.U. Khabriev. Moscow: Medicine Publ., 2005. 421–437 p. (In Russ.).

55. Galenko-Yaroshevsky PA, Kaverina NV, Kamkin AG, Turilova AI, Bogus SK, Sheikh-zade YuR. Methodical recommendations for preclinical study of antiarrhythmic drugs. Guidelines for conducting preclinical studies of drugs. Part 1 Moscow: “Grif and Co.: Publ., 2012. 385–416 p. (In Russ.).

56. Yuricheva YuA, Dzaurova KhM, Beliaeva MM, Mironov NY, Sokolov SF, Sherina TA, Golitsyn SP. The results of I phase clinical study of class III antiarrhythmic drug, tablet form. Siberian Journal of Clinical and Experimental Medicine. 2023;38(4):141–150 (In Russ.). https://doi.org/10.29001/2073-8552-2023-38-4-141-150

57. Atrial fibrillation. The state of the problem and prospects for creating a new antifibrillatory agent based on indole amino derivatives. Eds. by P.A. Galenko-Yaroshevsky, S.N. Alekseenko, S.G. Kanorsky. Krasnodar: Prosveshchenie-Yug, 2023. 747 p. (In Russ.)

58. Lawrance CP, Henn MC, Damiano RJ Jr. Surgical ablation for atrial fibrillation: techniques, indications, and results. Curr Opin Cardiol. 2015;30(1):58–64. https://doi.org/10.1097/HCO.0000000000000125

59. Swartz JF, Pellersels G, Silvers J, Patten L, Cervantez D. A catheter-based curative approach to atrial fibrillation in humans. Circulation. 1994;90:1–335

60. Haïssaguerre M, Jaïs P, Shah DC, Gencel L, Pradeau V, Garrigues S, Chouairi S, Hocini M, Le Métayer P, Roudaut R, Clémenty J. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1996;7(12):1132–1144. https://doi.org/10.1111/j.1540-8167.1996.tb00492.x

61. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–666. https://doi.org/10.1056/NEJM199809033391003

62. Wu C, Li X, Lv Z, Chen Q, Lou Y, Mao W, Zhou X. Second-generation cryoballoon versus contact force radiofrequency ablation for atrial fibrillation: an updated meta-analysis of evidence from randomized controlled trials. Sci Rep. 2021;11(1):17907. https://doi.org/10.1038/s41598-021-96820-8

63. Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, Hansen J, Blaauw Y, Maury P, Arentz T, Sommer P, Anic A, Anselme F, Boveda S, Deneke T, Willems S, van der Voort P, Tilz R, Funasako M, Scherr D, Wakili R, Steven D, Kautzner J, Vijgen J, Jais P, Petru J, Chun J, Roten L, Füting A, Lemoine MD, Ruwald M, Mulder BA, Rollin A, Lehrmann H, Fink T, Jurisic Z, Chaumont C, Adelino R, Nentwich K, Gunawardene M, Ouss A, Heeger CH, Manninger M, Bohnen JE, Sultan A, Peichl P, Koopman P, Derval N, Kueffer T, Reinsch N, Reddy VY. Impact of Left Atrial Posterior Wall Ablation During Pulsed-Field Ablation for Persistent Atrial Fibrillation. JACC Clin Electrophysiol. 2024;10(5):900–912. https://doi.org/10.1016/j.jacep. 2024.01.017

64. Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, Chierchia GB, Bulava A, Blaauw Y, Skala T, Fiala M, Duytschaever M, Szeplaki G, Schmidt B, Massoullie G, Neven K, Thomas O, Vijgen J, Gandjbakhch E, Scherr D, Johannessen A, Keane D, Boveda S, Maury P, García-Bolao I, Anic A, Hansen PS, Raczka F, Lepillier A, Guyomar Y, Gupta D, Van Opstal J, Defaye P, Sticherling C, Sommer P, Kucera P, Osca J, Tabrizi F, Roux A, Gramlich M, Bianchi S, Adragão P, Solimene F, Tondo C, Russo AD, Schreieck J, Luik A, Rana O, Frommeyer G, Anselme F, Kreis I, Rosso R, Metzner A, Geller L, Baldinger SH, Ferrero A, Willems S, Goette A, Mellor G, Mathew S, Szumowski L, Tilz R, Iacopino S, Jacobsen PK, George A, Osmancik P, Spitzer S, Balasubramaniam R, Parwani AS, Deneke T, Glowniak A, Rossillo A, Pürerfellner H, Duncker D, Reil P, Arentz T, Steven D, Olalla JJ, de Jong JSSG, Wakili R, Abbey S, Timo G, Asso A, Wong T, Pierre B, Ewertsen NC, Bergau L, Lozano-Granero C, Rivero M, Breitenstein A, Inkovaara J, Fareh S, Latcu DG, Linz D, Müller P, Ramos-Maqueda J, Beiert T, Themistoclakis S, Meininghaus DG, Stix G, Tzeis S, Baran J, Almroth H, Munoz DR, de Sousa J, Efremidis M, Balsam P, Petru J, Küffer T, Peichl P, Dekker L, Della Rocca DG, Moravec O, Funasako M, Knecht S, Jauvert G, Chun J, Eschalier R, Füting A, Zhao A, Koopman P, Laredo M, Manninger M, Hansen J, O’Hare D, Rollin A, Jurisic Z, Fink T, Chaumont C, Rillig A, Gunawerdene M, Martin C, Kirstein B, Nentwich K, Lehrmann H, Sultan A, Bohnen J, Turagam MK, Reddy VY. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024;30(7):2020–2029. https://doi.org/10.1038/s41591-024-03114-3

65. Reddy VY, Mansour M, Calkins H, d’Avila A, Chinitz L, Woods C, Gupta SK, Kim J, Eldadah ZA, Pickett RA, Winterfield J, Su WW, Waks JW, Schneider CW, Richards E, Albrecht EM, Sutton BS, Gerstenfeld EP; ADVENT Investigators. Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden. J Am Coll Cardiol. 2024;84(1):61–74. https://doi.org/10.1016/j.jacc.2024.05.001

66. Providencia R, Ali H, Creta A, Barra S, Kanagaratnam P, Schilling RJ, Farkowski M, Cappato R. Catheter ablation for atrial fibrillation and impact on clinical outcomes. Eur Heart J Open. 2024;4(4):oeae058. https://doi.org/10.1093/ehjopen/oeae058

67. van der Heijden CAJ, Aerts L, Chaldoupi SM, van Cruchten C, Kawczynski M, Heuts S, Bidar E, Luermans JGLM, Maesen B. Hybrid atrial fibrillation ablation. Ann Cardiothorac Surg. 2024;13(1):54–70. https://doi.org/10.21037/acs-2023-afm-0129

68. Lee SR, Choi EK, Lee SW, Han KD, Oh S, Lip GYH. Clinical Impact of Early Rhythm Control and Healthy Lifestyles in Patients With Atrial Fibrillation. JACC Clin Electrophysiol. 2024;10(6):1064–1074. https://doi.org/10.1016/j.jacep.2024.02.016

69. Shin ED, Tran HN, Ramalingam ND, Liu T, Fan E. Rate Versus Rhythm Control for Atrial Fibrillation. Perm J. 2024;28(1):81–85. https://doi.org/10.7812/TPP/23.151